The importance of effective early phase insulin secretion

British Journal of Diabetes and Vascular Disease

Volumn 5, Issue 4, 2005, Pages 198-202

  Del Prato, Stefano ^a   Miccoli, Roberto ^b   Penno, Giuseppe ^b  

^a CISANELLO HOSPITAL   (Italy)

^b NONE

Author keywords

Impaired acute insulin secretion; Insulin resistance; Type 2 diabetes

Indexed keywords

GLICLAZIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; INSULIN LISPRO;

DIABETES CONTROL; DISEASE CONTROL; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; POSTPRANDIAL STATE; REVIEW; RISK ASSESSMENT;

EID: 24944560358     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514050050040401     Document Type: Review

References (39)

1. Del Prato S, Maran A, Beck-Nielsen H. The plurimetabolic syndrome in the European Population: the experience of the European Group on Insulin Resistance (EGIR). Insulin Resistance, Metabolic Diseases and Diabetic Complications. In: Crepaldi G, Tiengo A, Del Prato S. eds. Excerpta Medica. International Congress Series 1177, Internal Medicine. Elsevier, Amsterdam, 1999:25-30.
2. Haffner SM, Miettinen H, Gaskill SP, Stern M. Decreased insulin action and insulin secretion predict the development of impaired glucose tolerance. Diabetologia 1996;39:1201-07.
3. Bonora E, Formentini G, Calcaterra F et al. HOMA-Estimated Insulin Resistance is an Independent Predictor of Cardiovascular Disease in Type 2 Diabetic Subjects: Prospective data from the Verona Diabetes Complications Study. Diabetes Care 2002; 25:1135-41.
4. Brunzell JD, Robertson RP, Lerner RL et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 1976;42:222-9.
5. Del Prato S, Ferrannini E, DeFronzo RA. Evaluation of Insulin Sensitivity in Man. In: Methods in Diabetes Research, Vol. II, Clarke WL, Larner J. Pohl SL eds, J. Wiley & Sons, 1986:35-76.
6. Toffolo G, Bergman RN, Finegood DT, Bowden CR, Cobelli C. Quantitative estimation of beta cell sensitivity to glucose in the intact organism: a minimal model of insulin kinetics in the dog. Diabetes 1980;29:979-90.
7. Yoneda H, Ikegami H, Yamamoto et al. Analysis of early-phase insulin responses in nonobese subjects with mild glucose intolerance. Diabetes Care 1992;15:1517-21.
8. Cretti A, Lehtovirta M, Bonora E et al. Assessment of beta-cell function during the oral glucose tolerance test by a minimal model of insulin secretion. Eur J Clin Invest 2001; 31:405-16.
9. Mari A. Mathematical modeling in glucose metabolism and insulin secretion. Curr Opin Clin Nutr Metab Care 2002; 5:495-501.
10. Holman RR. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract 1998; 40(suppl):S21-S25.
11. Larsson H, Ahren B. Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagons secretion in post-menopausal women with impaired glucose tolerance. Diabetes Care 2000;23:650-7.
12. Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation 2000;101:975-80.
13. Lundgren H, Bengtsson C, Blohmè G, Lapidus L, Waldeström J. Fasting serum insulin concentration and early insulin response as risk determinants for developing diabetes. Diabet Med 1990;7:407-13.
14. Kosaka K, Kuzuya T, Hagura R, Yoshinaga H. Insulin response to oral glucose load is consistently decreased in established non-insulin-dependent diabetes mellitus: the usefulness of decreased early insulin response as a predictor of non-insulin-dependent diabetes mellitus. Diabet Med 1996;13:S109-S119.
15. Hanson RL, Pratley RE, Bogardus C et al. Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am J Epidemiol 2000;151:190-8.
16. Del Prato S, Marchetti P, Bonadonna RC. Phasic insulin release and metabolic regulation in type 2 diabetes. Diabetes 2002;51(suppl 1):S109-S116.
17. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104:787-94.
18. Weyer C, Tataranni PA, Bogardus C, Prately RE. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of Type 2 diabetes development. Diabetes Care 2001;24:89-94.
19. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab 2005;90:493-500.
20. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA. San Antonio metabolism study. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 2004;47:31-9.
21. Bruce DG, Storlien LH, Furler SM, Chisholm DJ. Cephalic phase metabolic responses in normal weight adults. Metabolism 1987; 36:721-5.
22. Mitrakou A, Kelley D, Mokan M et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992;326:22-9.
23. Cherrington AD, Sindelar D, Edgerton D, Steiner K, McGuinness OP. Physiological consequences of phasic insulin release in the normal animal. Diabetes 2002;51(suppl 1):S103-S108.
24. Luzi L, DeFronzo RA. Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. Am J Physiol 1989;257:E241-E246.
25. Calles-Escandon J, Robbins DC. Loss of early phase of insulin release in humans impairs gucose tolerance and blunts thermic effect of glucose. Diabetes 1987;36:1167-72.
26. Basu A, Alzaid A, Dinneen S, Caumo A, Cobelli C, Rizza RA. Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance. J Clin Invest 1986; 97:2351-61.
27. Sartor G, Schersten B, Carlstrom S, Melander A, Norden A, Persson G. Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes 1980;29:41-9.
28. Knowler WC, Barrett-Connor E, Fowler SE et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
29. Tuomilehto J, Lindstrom J, Eriksson JG et al. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50
30. Del Prato S, Leonetti F, Simonson DC, Sheean P, Matsuda M, DeFronzo RA. Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. Diabetologia 1994;37:1025-35.
31. Kashyap S, Belfort R, Gastaldelli A et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 2003;52:2461-74.
32. Bruce DG, Chisholm DJ, Storlien LH, Kraegen EW. Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes. Diabetes 1988;37:736-44.
33. Bruttomesso D, Pianta A, Mari A et al. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes 1999;48:99-105.
34. Hosker JP, Rudenski AS, Burnett MA et al. Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy. Metabolism 1989;38:767-72.
35. Juhl CB, Porksen N, Pincus SM, Hansen AP, Veldhuis JD, Schmitz O. Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes. Diabetes 2001;50:1778-84.
36. Dornhorst A. Insulinotropic meglitinide analogues. Lancet 2001;358:1709-16.
37. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004;287:E199-E206.
38. Rachman J. Potential therapies mimicking the effects of glucagon-like peptide-1 for the treatment of type 2 diabetes. Diabet Med 2004;21 (suppl 1):18-20.
39. Wiedeman PE, Trevillyan JM. Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes. Curr Opin Investig Drugs 2003;4:412-20.